Navigation Links
A Discovery That may Lessen a Health Disparity

Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated// an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia. Results of the study were presented today by lead author Jin-Ping Lai, M.D., Ph.D., at the American Association for Cancer Research annual meeting.

Nasopharyngeal cancer disproportionately affects people living in southern China and surrounding areas, as well as recent Southeast Asian immigrants to the United States, says the American Cancer Society. It also is common in Alaska Natives and is 50 percent more likely to occur in blacks than in whites.

SULF2, a recently identified heparin-degrading endosulfatase, appears to be significantly overexpressed in nasopharyngeal cancers, providing hope of the eventual ability to predict recurrence and subsequent prognosis after radiation therapy, the standard treatment for nasopharyngeal cancer.

The researchers examined tumor tissue from 55 patients with squamous cell carcinoma of the nasopharynx, otherwise known as nasopharyngeal cancer. All patients had been treated by radiation therapy and follow-up was conducted for 10 years. The investigators found that rates of early recurrence (within five years) were significantly higher for individuals with high levels of SULF2 in the tumor (expressed in more than 10 percent of cancer cells). These same individuals were much more likely to die within 10 years.

“Learning more about the way a specific type of cancer develops, and what proteins it produces as it grows, helps us find better ways to treat that cancer,” said Dr. Lai, who is a cancer researcher at Mayo Clinic with background as an otolaryngologist. “With nasopharyngeal cancer, we think this new enzyme may help solve the puzzle.”

Locating the enzyme also allowed Dr. Lai and his colleagues to make the antibody for SULF2, which is a step leading to an effective treatment for nasopharyngeal cancer. SULF2 also appears to be a factor in liver cancer, a link under investigation by the Mayo researchers.

“We continue to look for ways to combat health disparities in the United States and throughout the world,” said Lewis Roberts, M.B.Ch.B., Ph.D., the study’s principal investigator and a gastroenterologist at Mayo Clinic. “Our research into SULF2 suggests a number of promising possibilities for the development of more effective treatments for cancer.”

Source-EurekalertMED/V
'"/>




Related medicine news :

1. Discovery of bone gene
2. New Discovery May Help Treat Infertility
3. New Discovery to Increase Survival of Breast cancer Patients
4. Discovery of World’s smallest laser
5. Discovery of a built-in fat sensor
6. OHSU Researchers Announce New Discovery
7. Discovery Of New Molecule Could Solve Cancer Spread Mystery
8. Discovery Of Human Skeletons Could Unfold Facts About By-Gone Ages
9. New Discovery Shows That Brain Could repair Itself After Stroke
10. New Sleep Gene Discovery Wakes Up Scientists
11. Discovery of Elevated Amyloid Peptide levels could lead to Alzheimer’s Preventio
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology: